Slides
Page 1
gsk.com GlaxoSmithKline Pharmaceuticals Limited
Page 2
2 Bhushan Akshikar, Managing Director Mr. Bhushan Akshikar has been the MD of GSK India since Q3 2022. He brings over 15 years of leadership experience within GSK in key roles across India, Middle East, Russia CIS & Africa region. Prior to joining GSK, Bhushan spent 15 years with Johnson & Johnson, in local and regional positions in India, S. Korea and Belgium. Mr. Ronojit Biswas has been the CFO of GSK India since April 2026. He brings over 25 years of experience across global finance roles, spanning India, Vietnam, Singapore, Brazil and the UK. Prior to this role, Ronojit served as Senior Finance Director – Global Product Strategy for the General Medicines Therapy Area and has previously been Regional Controller (International) and CFO for GSK’s Brazil and Vietnam businesses. Ronojit Biswas, Chief Financial Officer
Page 3
3 GSK India’s Key Focus areas to drive growth aligned to global priorities Deliver growth Established portfolio – deliver competitive performance; Innovative portfolio – deliver ambition Accelerate R&D Focus on innovation & accelerate launch of pipeline products Simplify how we work Reduce complexity, focus resources on what matters most and embrace AI/tech to drive agility
Page 4
4 IPM Q1 FY27 IPM grew at 13.5%, GSK grew faster than its Rep Market GSK’s Rep market grew at 10% with both Vx and Gen Med outperforming the market Source: IQVIA Jun’26 dataset (MQT); *includes all Gen Med & Vaccine brands except GoA portfolio & the discontinued brands GSK portfolio* has maintained its leadership with 23% share in rep market Rep mar GSK portfolio 10% 11% Price: 2.4%, Vol: 4.4%, NI: 1.8% GSK Gen Med portfolio* has maintained its leadership with 22% share in rep market Rep mar GSK Ged Med portfolio 9% 11% Price: 3.2%, Vol: 3.2%, NI: 3% GSK Vx portfolio* has maintained its leadership with 27% share in rep market Rep mar GSK Vx portfolio 20% 14% Price: -2%, Vol: 13.3%, NI: 5.4% GSK’s performance in metro class and specialties outgrew the market Metros T1 T2-6 Rural 33% 31% 20% 16% 12% 11.1% 7.4% 8.2% GPs continue to dominate with 40% Rxns volume and growth faster than Specialty and Super specialty Rxns 5.5% 4.9% GP Specialty Super Spec 4.8% 40% 36% 24% 32% (+4.3%) 32% (+1.6%) 20% (+2%) 16% (-0.6%) 45% (4.3%); 43% (4.9%) ; 12% (-0.7%) GSK GSK IPM IPM IPM sees growth largely on account of price. 13.6% Apr-May’26 IPM Gr. Chronic grew better vs acute increasing its industry contribution Acute Chronic % Growth 11%60% 40% MNCs ahead of Indian players with respect to growth Indian MNCs 84% 16% 17% 13% 15% % Growth 8.7% 1.9% 3.0% Volume NI Price Within Acute, key therapies like Pain, derma grew at 11%; AI grew slower 16.9 8.5 10 17.3 13.2 11.3 16.3 11.3 12.9 12.1 11.5 18.5 CARDIAC ANTI INF GASTRO ANTI DIABETIC PAIN RESPIRATORY VIT/MIN/NUT DERMA NEURO / CNS GYNAEC. HORMONES VACCINES % Value Growth 13.3 10.5 10.5 9.0 8.7 7.6 7.5 6.8 6.0 4.7 1.5 1.5 % Contri
Page 5
5 GSK’s key brands remained competitive in the market in Q1 FY27 SPECIALTYGENERAL MEDICINES VACCINES Gen Meds1 market share improved (+0.6%val MS gain, Val EI 101); key brands delivered competitive performance 1 2 Established Vaccines continues to lead the overall Vx market with 26.1% Val MS2 Unit EI 95 & Val EI 93 3 Establishing adult immunization as a category through Shingrix; driving 2026 growth through the CVMD opportunity 2.6k Rxers for (39% YOY growth) 4 Building equity in the Respiratory Segment 3500+ Severe asthma patients benefitted Strong foundation in Oncology 5 Source: IQVIA Jun'26 dataset (MQT), Internal data; 1excludes GOA; 2 MAT Val MS; 3 Distributed brands includes the GoApptiv portfolio, 4Both F2F+ Digital New Patient Uptake Monthly units (maintaining >19% vs avg. units post LoE sales post LOE in Apr 2025) New Patient Update MS Q1 FY26 Q1 FY27 Val 26.7 26.6 Unit 33.3 33.9 Improving our SoV and Elevating customer experience through digital innovation 7.7Mn+ Touchpoints4 360K+ Unique HCPs reached4 Brand Val EI Val MS (G/L) Val Gr (Q1 FY27) (Q1 FY27) (Q1 FY27) Augmentin 105 22% (1.0%) 12.80% Calpol 106 31.2% (1.6%) 8.10% T-Bact 105 57.5% (2.6%) 17.90% Ceftum 101 32.7% (0.2%) 7.60% Key Promoted Brands 100 23.4% (0%) 11.30% *1% Unit Market Share Gain
Page 6
6 Financial Highlights : Q1 FY 26-27 (Standalone) Revenue ₹924cr Growth +15% PAT ₹253cr Margin: 27.6% (+200 bps) Growth +24% * Innovation = Oncology (Jemperli + Zejula) + New Respiratory (Nucala + Trelegy) + Adult Vaccines (Shingrix) Source: GSK Standalone reported data EBITDA ₹293cr Margin: 31.7% (+50 bps) Growth +17% Delivering strong growth with continued portfolio transformation Revenue growth +15% Sales growth driven by execution excellence; portfolio transformation strategy and favourable base effect compared to PY Innovation* portfolio accounts for 7% (PY 4%) of total sales, driving 1/4th of headline growth. Building momentum with Oncology launches & New respiratory General medicines growth led by brands Augmentin, Ceftum and T-Bact Pead Vaccines continued leadership in the self pay private pediatric market Shingrix delivered growth +65% driven with HCPs and HCOs engagement to shape the category EBITDA margin +50 bps (YoY) EBITDA improved on the back of gross margin improvement Gross margin improved +150 bps on pricing and favorable mix offset by higher EGOL and other costs SG&A as a % of sales higher by 1%, mainly driven by investments in core brands & new product PAT +200 bps (YoY) PAT stepped up on consistent gross margin improvement; one-off dividend from Biddle Sawyer Limited (100% subsidiary) EPS for Q1 @ 14.95 (+24%) Sustained focus to strengthen and optimize the balance sheet
Page 7
7 Consistent competitive performance & profitability improvement with portfolio transformation 27 28 28.3 31.9 30.7 34.3 31.2 34.4 35.9 35.2 31.7 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Improving profitability EBITDA Margins% Market share % * Market share of Key promoted brands in its rep market; Key promoted brands - Augmentin, Calpol, Ceftum, T-bact, CCM, Cobadex CZS, Eltroxin, Tenovate,Neosporin, Supacef Category growth Portfolio transformation Innovation Key promoted brands Est. Vx Source: Internal data till Mar 2026; IQVIA Jun’26 26.3 27.1 27.8 27.4 26.5 27.6 27.9 27.4 27.6 28 27.8 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Competitive performance Upcoming Launches
Page 8
gsk.comgsk.comgsk.com End of Presentation